Scientists at NYU’s Center for Genomics & Systems Biology have created a 3D model that could advance cancer screening and ...

Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value ...

Most OVT clinical trials have been conducted on late-stage, metastatic cancer. But in the past few years, scientists have ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with me ...

Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.

Received a "Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) to evaluate amezalpat in combination ...

A scientist who was diagnosed with stage 3 cancer treated herself using lab-grown viruses, a method researchers say is 'not ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

An expert told CURE that Trodelvy's side effects, such as neutropenia and fatigue, can often be managed through dose ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

In September 2024, Checkpoint presented longer-term data from its pivotal trial of cosibelimab in locally advanced and metastatic cSCC during the European Society for Medical Oncology ("ESMO") ...